Cytosorbents (NASDAQ:CTSO) Earns Hold Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Cytosorbents (NASDAQ:CTSO) in a report published on Tuesday. The firm issued a hold rating on the medical research company’s stock.

Separately, D. Boral Capital reiterated a “buy” rating and issued a $10.00 target price on shares of Cytosorbents in a research report on Tuesday, February 25th. Two research analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Cytosorbents presently has a consensus rating of “Moderate Buy” and a consensus price target of $4.67.

Cytosorbents Price Performance

Shares of CTSO opened at $1.09 on Tuesday. The company has a quick ratio of 1.58, a current ratio of 1.97 and a debt-to-equity ratio of 1.06. The stock has a market cap of $59.60 million, a PE ratio of -3.03 and a beta of 0.78. Cytosorbents has a 12-month low of $0.70 and a 12-month high of $1.61. The business has a 50-day simple moving average of $1.07 and a two-hundred day simple moving average of $1.05.

Hedge Funds Weigh In On Cytosorbents

Several large investors have recently bought and sold shares of the company. Millennium Management LLC acquired a new stake in shares of Cytosorbents in the fourth quarter valued at about $30,000. Renaissance Technologies LLC increased its stake in shares of Cytosorbents by 10.6% in the fourth quarter. Renaissance Technologies LLC now owns 88,020 shares of the medical research company’s stock valued at $80,000 after buying an additional 8,400 shares during the period. Northern Trust Corp increased its stake in shares of Cytosorbents by 22.3% in the fourth quarter. Northern Trust Corp now owns 91,560 shares of the medical research company’s stock valued at $83,000 after buying an additional 16,701 shares during the period. Raymond James Financial Inc. acquired a new stake in shares of Cytosorbents in the fourth quarter valued at about $99,000. Finally, Geode Capital Management LLC increased its stake in shares of Cytosorbents by 7.5% in the third quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock valued at $701,000 after buying an additional 32,415 shares during the period. 32.87% of the stock is currently owned by institutional investors.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.